First National Bank of Mount Dora Trust Investment Services Buys 84 Shares of Laboratory Co. of America Holdings (NYSE:LH)

First National Bank of Mount Dora Trust Investment Services increased its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 0.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 11,654 shares of the medical research company’s stock after buying an additional 84 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Laboratory Co. of America were worth $2,672,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. SouthState Corp bought a new stake in Laboratory Co. of America in the 3rd quarter valued at about $28,000. Horizon Bancorp Inc. IN bought a new stake in Laboratory Co. of America in the 3rd quarter valued at about $29,000. Fortitude Family Office LLC boosted its holdings in Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 100 shares during the period. Riverview Trust Co boosted its holdings in Laboratory Co. of America by 172.6% in the 3rd quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 107 shares during the period. Finally, Concord Wealth Partners boosted its holdings in Laboratory Co. of America by 43.3% in the 3rd quarter. Concord Wealth Partners now owns 172 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 52 shares during the period. Institutional investors own 95.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LH. Barclays boosted their target price on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the company an “equal weight” rating in a research report on Friday, October 25th. Piper Sandler boosted their target price on shares of Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Bank of America boosted their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Jefferies Financial Group restated a “buy” rating and issued a $275.00 target price (up from $265.00) on shares of Laboratory Co. of America in a research report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $260.54.

Laboratory Co. of America Trading Down 0.1 %

LH opened at $238.44 on Friday. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week high of $247.99. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The firm has a market capitalization of $19.94 billion, a price-to-earnings ratio of 46.12, a PEG ratio of 1.73 and a beta of 1.06. The company’s 50 day moving average price is $234.80 and its two-hundred day moving average price is $225.60.

Laboratory Co. of America (NYSE:LH) last posted its earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.02. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The firm had revenue of $3.28 billion for the quarter, compared to analyst estimates of $3.26 billion. During the same period in the previous year, the firm posted $3.38 EPS. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, research analysts predict that Laboratory Co. of America Holdings will post 14.51 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.21%. Laboratory Co. of America’s dividend payout ratio is currently 55.71%.

Insider Activity

In related news, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the transaction, the director now directly owns 12,722 shares of the company’s stock, valued at $2,989,670. This represents a 7.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Glenn A. Eisenberg sold 11,711 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $240.43, for a total transaction of $2,815,675.73. Following the transaction, the executive vice president now directly owns 31,289 shares in the company, valued at approximately $7,522,814.27. This represents a 27.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,572 shares of company stock valued at $6,145,209. 0.85% of the stock is currently owned by insiders.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.